Abstract:Aims/hypothesis: Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. A growing number of T cell-directed therapeutics have demonstrated partial therapeutic efficacy, with anti-CD3 (α-CD3) representing the only regulatory agency-approved drug capable of slowing disease progression through a mechanism involving the induction of partial T cell exhaustion. There is an outstanding need to augment the durability and effectiveness of T cell targeting by directly restraining proinflammatory T helper type 1 (Th1) and type 1 cytotoxic CD8+ T cell (Tc1) subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a novel strategy for reducing diabetes incidence in the NOD mouse model using a blocking monoclonal antibody targeting the type 1 diabetes-risk associated T cell co-stimulatory receptor, CD226. Methods: Female NOD mice were treated with anti-CD226 between 7-8 weeks of age and then monitored for diabetes incidence and therapeutic mechanism of action. Results: Compared to isotype-treated controls, anti-CD226 treated NOD mice showed reduced insulitis severity at 12 weeks and decreased disease incidence at 30 weeks. Flow cytometric analysis performed five weeks post-treatment demonstrated reduced proliferation of CD4+ and CD8+ effector memory T cells in spleens of anti-CD226 treated mice. Phenotyping of pancreatic Tregs revealed increased CD25 expression and STAT5 phosphorylation following anti-CD226, with splenic Tregs displaying augmented suppression of CD4+ T cell responders in vitro. Anti-CD226 treated mice exhibited reduced frequencies of islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP)-reactive CD8+ T cells in the pancreas, using both ex vivo tetramer staining and single-cell T cell receptor sequencing (scTCR-seq) approaches. 51Cr-release assays demonstrated reduced cell-mediated lysis of beta-cells by anti-CD226-treated autoreactive cytotoxic T lymphocytes. Conclusions/interpretation: CD226 blockade reduces T cell cytotoxicity and improves Treg function, representing a targeted and rational approach for restoring immune regulation in type 1 diabetes.

CD226 Attenuates Treg Proliferation via Akt and Erk Signaling in an EAE Model

CD226 Attenuates Treg Suppressive Capacity Via CTLA-4 and TIGIT During EAE

CD226 Ligation Protects Against EAE by Promoting IL-10 Expression Via Regulation of CD4+ T Cell Differentiation.

CD226 deficiency attenuates the homeostasis and suppressive capacity of Tr1 cells

Manipulation of Qa‐1‐restricted CD8 Suppressor Cell Activity in Experimental Autoimmune Encephalomyelitis

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Expression of CD226 antagonizes apoptotic cell death in murine thymocytes.

Regulation Of Cd8(+) Regulatory T Cells: Interruption Of The Nkg2a-Qa-1 Interaction Allows Robust Suppressive Activity And Resolution Of Autoimmune Disease

CD226 Protein is Involved in Immune Synapse Formation and Triggers Natural Killer (NK) Cell Activation Via Its First Extracellular Domain*

Costimulatory Molecule CD226 Regulates Atopic Dermatitis in a Mouse Model

Cd1-Dependent Regulation of Chronic Central Nervous System Inflammation in Experimental Autoimmune Encephalomyelitis

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells

CD4+CD25+ regulatory T cells ex vivo generated from autologous naïve CD4+ T cells suppress EAE progression

Cd4(+)T Cell Specific B7-H1 Selectively Inhibits Proliferation Of Naive T Cells And Th17 Differentiation In Experimental Autoimmune Encephalomyelitis

Mouse Cd11b(+)Gr-1(+) Myeloid Cells Can Promote Th17 Cell Differentiation And Experimental Autoimmune Encephalomyelitis

Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells

miR-20a suppresses Treg differentiation by targeting Map3k9 in experimental autoimmune encephalomyelitis

CXCL12 (SDF-1α) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells

Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function

Embelin Suppresses Dendritic Cell Functions and Limits Autoimmune Encephalomyelitis Through the TGF-β/β-catenin and STAT3 Signaling Pathways.